Zydus Cadila has gotten final endorsement from the USFDA to showcase Atazanavir Capsules (US RLD: Reyataz&#x2122; Capsules) in the qualities of 150 mg, 200 mg and 300 mg.

Atanazavir, an antiretroviral medicate, is utilized to treat contamination of the Human Immunodeficiency Virus (HIV). It is utilized in blend with other antiretroviral medications to treat HIV-1 contamination.

The medication will be produced at the gathering's assembling office at SEZ, Anmedabad.

The gathering presently has 291 endorsements and has so far documented more than 390 ANDAs since the initiation of the recording procedure in FY 2003-04.

Portions of CADILA HEALTHCARE LTD. was last exchanging BSE at Rs.362.9 when contrasted with the past close of Rs. 354. The absolute number of offers exchanged during the day was 267884 in more than 4516 exchanges.

The stock hit an intraday high of Rs. 363.9 and intraday low of 353.75. The net turnover during the day was Rs. 96147344.